company background image
4591 logo

Ribomic TSE:4591 Stock Report

Last Price

JP¥80.00

Market Cap

JP¥3.3b

7D

0%

1Y

-18.4%

Updated

22 Dec, 2024

Data

Company Financials

Ribomic Inc.

TSE:4591 Stock Report

Market Cap: JP¥3.3b

4591 Stock Overview

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. More details

4591 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 5.8% per year over past 5 years

Makes less than USD$1m in revenue (¥2M)

Does not have a meaningful market cap (¥3B)

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Ribomic Inc. Competitors

Kringle Pharma

TSE:4884

JP¥5.5b

Modalis Therapeutics

TSE:4883

JP¥6.9b

Oncolys BioPharma

TSE:4588

JP¥12.6b

Transgenic Group

TSE:2342

JP¥3.0b

Price History & Performance

Summary of share price highs, lows and changes for Ribomic
Historical stock prices
Current Share PriceJP¥80.00
52 Week HighJP¥123.00
52 Week LowJP¥60.00
Beta0.60
1 Month Change-3.61%
3 Month Change-4.76%
1 Year Change-18.37%
3 Year Change-90.05%
5 Year Change-84.00%
Change since IPO-95.79%

Recent News & Updates

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Oct 30
Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Jul 02
We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Recent updates

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Oct 30
Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Jul 02
We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Shareholder Returns

4591JP BiotechsJP Market
7D0%-1.7%-1.5%
1Y-18.4%18.5%13.7%

Return vs Industry: 4591 underperformed the JP Biotechs industry which returned 18.5% over the past year.

Return vs Market: 4591 underperformed the JP Market which returned 13.7% over the past year.

Price Volatility

Is 4591's price volatile compared to industry and market?
4591 volatility
4591 Average Weekly Movement4.5%
Biotechs Industry Average Movement6.9%
Market Average Movement3.6%
10% most volatile stocks in JP Market7.3%
10% least volatile stocks in JP Market1.9%

Stable Share Price: 4591 has not had significant price volatility in the past 3 months compared to the JP market.

Volatility Over Time: 4591's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200324Yoshikazu Nakamurawww.ribomic.com

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

Ribomic Inc. Fundamentals Summary

How do Ribomic's earnings and revenue compare to its market cap?
4591 fundamental statistics
Market capJP¥3.25b
Earnings (TTM)-JP¥949.00m
Revenue (TTM)JP¥2.00m

1,626x

P/S Ratio

-3.4x

P/E Ratio

Is 4591 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4591 income statement (TTM)
RevenueJP¥2.00m
Cost of RevenueJP¥0
Gross ProfitJP¥2.00m
Other ExpensesJP¥951.00m
Earnings-JP¥949.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-23.35
Gross Margin100.00%
Net Profit Margin-47,450.00%
Debt/Equity Ratio0%

How did 4591 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 13:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ribomic Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Kiyokazu YamazakiIchiyoshi Research Institute Inc.